Highlights

Regulatory Developments

  • Update from the EU Commission: Regulatory changes for substances in nanoforms

  • ECHA strategy on substances in nanoforms

  • Update on the OECD Test Guidelines for

    nanomaterials safety testing

    Nano-Forms and Human Health

  • Grouping concept for Nanomaterials

  • The EFSA guidance on the risk assessment

    of the application of nanoscience and nanotechnologies in the food and feed chain – potential risks for human health

  • Overarching characteristics of nanoforms that could have impact on health

  • Updates in search for unifying nanoscale features that impact living organisms

    Nano-Forms in the Environment

  • New developments in modelling the flows of nanomaterials to the environment

  • Environmental impact of TiO2 nanoparticles used as UV filters in sunscreen cosmetics

  • Nanomaterials and nano-plastics in aquatic

    environments

The Experts

Björn Braun Evonik Resource Efficiency | Francesco Cubadda Italian National Institute of Health (ISS)/EFSA Working Group on nanoscience and nanotechnology in food/feed | Kenneth A. Dawson Centre for BioNano Interactions, University College Dublin | Laurence Deydier StephanEuropean Chemicals Agency (ECHA) | Tamara Galloway University of Exeter | Mar Gonzalez Organisation for Economic Co-operation and Development (OECD) | Andrej Kobe European Commission | Jerome Labille European Centre for Research and Teaching in Environmental Geoscience (Cerege) | Iseult Lynch University of Birmingham/Facility for Environmental Nanomaterials Analysis and Characterisation (FENAC) | Bernd Nowack Swiss Federal Laboratories for Materials Science and Technology (EMPA) | Karsten Schlich Fraunhofer Institute for Molecular Biology and Applied Ecology | Katharina Schwarz Fraunhofer Institute for Toxicology and Experimental Medicine | Blanca Serrano The European Chemical Industry Council (CEFIC) | Christine Spirlet International Zinc Association | Michael Stintz Technical University Dresden | Lang TranBritish Institute of Occupational Medicine (IOM) | Karin Wiench BASF